Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside

Abstract : There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.
Type de document :
Article dans une revue
Oncotarget, Impact journals, 2016
Liste complète des métadonnées

Littérature citée [25 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01319327
Contributeur : Elizabeth Bernardo <>
Soumis le : vendredi 20 mai 2016 - 16:05:23
Dernière modification le : jeudi 15 mars 2018 - 14:10:54

Fichier

PDFEqu14.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

  • HAL Id : inserm-01319327, version 1
  • PUBMED : 27172791

Collections

Citation

Julien Fleurence, Denis Cochonneau, Sophie Fougeray, Lisa Oliver, Fanny Geraldo, et al.. Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside. Oncotarget, Impact journals, 2016. 〈inserm-01319327〉

Partager

Métriques

Consultations de la notice

156

Téléchargements de fichiers

115